Sustandrol 250mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Usage

1. Inspect the printed batch number and expiry code on the outer carton against supplier documentation before opening any ampoule.
2. Check each ampoule for visible particulate matter, discolouration, or cracks — GMP release testing covers potency and endotoxin, but physical inspection at point of use remains the user's responsibility.
3. Score and snap the ampoule neck using the coloured break-ring indicator; the glass-fusion seal has already been integrity-tested during production.
4. Draw the full 1 ml volume using a fresh, sterile syringe — the single-dose format means the entire contents are intended for one administration with no remainder to store.
5. Administer via deep intramuscular injection (gluteus, vastus lateralis, or deltoid) using an appropriate needle gauge; rotate injection sites across the 10-ampoule supply to minimise local tissue accumulation.
6. Store remaining unopened ampoules in their sealed carton at 15–25 °C, away from direct light and moisture, consistent with ICH Q1A(R2) stability validation data printed on the label.

Warnings

Frequently asked questions

Who manufactures Sustandrol and where is it produced?

Sustandrol is manufactured by Balkan Pharmaceuticals at their pharmaceutical production facility in Chișinău, Republic of Moldova. The site operates under EU GMP principles — including Annex 1 requirements for sterile injectables — and is subject to periodic regulatory inspections. Balkan Pharmaceuticals was established in 2006 with an explicit focus on producing anabolic preparations to certified pharmaceutical standards rather than grey-market quality levels.

What does GMP Standard mean for an injectable testosterone product like Sustandrol?

GMP (Good Manufacturing Practice) Standard means that every production step for Sustandrol — cleanroom environments, raw-material specifications, filling, sealing, and batch release — follows validated, documented procedures under regulatory oversight. For sterile injectables, EU GMP Annex 1 adds environmental monitoring and container-closure integrity requirements. The result is that each ampoule reaching the end user carries a traceable batch record confirming it met defined sterility, potency, and endotoxin standards.

How does Balkan Pharmaceuticals batch-test Sustandrol before release?

Each Sustandrol batch undergoes two mandatory analytical tests before shipment. HPLC (high-performance liquid chromatography) confirms that total testosterone ester content meets the 250 mg/ml label claim within the validated acceptance range and verifies the relative proportions of all four ester fractions. LAL (Limulus Amebocyte Lysate) testing independently measures bacterial endotoxin levels in the finished oil solution, ensuring they fall below the parenteral limit set by the European Pharmacopoeia.

Why does Sustandrol come in 10x1ml single-dose ampoules rather than a multi-dose vial?

The 10 × 1 ml single-dose format means each ampoule is opened and used once, eliminating repeated-puncture contamination risk inherent in multi-dose vials. Glass-fusion sealing during the filling-and-closing process creates an airtight, sterility-verified closure validated as part of container-closure integrity testing under GMP requirements. Every ampoule in the box carries the same batch traceability code, linking each individual dose to the full release documentation for that production lot.

At 250mg/ml, is Sustandrol a lower concentration than other testosterone blends, and does that matter?

250 mg/ml is the standard concentration established in the original clinical specification for four-ester testosterone blends and remains the most widely studied dose density for this formulation type. It is analytically confirmed per-batch by HPLC at Balkan Pharmaceuticals' facility. For users, 250 mg/ml in a 1 ml ampoule delivers a clean, precisely measured single injection volume — avoiding the concentration variability that can appear in higher-concentration compounded preparations where analytical validation may be less rigorous. (2) angle_used

Manufacturer

Sustandrol's supply chain begins and ends with accountable, documented logistics. Balkan Pharmaceuticals distributes its injectable portfolio — including Sustandrol — through an authorised wholesale network operating under GDP (Good Distribution Practice) guidelines, which require that temperature conditions, storage duration, and chain-of-custody records are maintained from the Chișinău dispatch point to the receiving warehouse. Each shipment is accompanied by batch release certificates generated at the production facility, allowing distributors and end-point operators to verify that the HPLC and LAL analytical data for a specific lot number matches the physical product in their hands. The 10 × 1 ml carton format was selected in part to facilitate this logistics model: individual unit counts are immediately auditable, palletisation is standardised, and the absence of multi-dose shared containers removes any ambiguity about whether a product has been accessed or partially used in transit. Balkan Pharmaceuticals maintains GDP-aligned temperature monitoring across its distribution chain, with the validated storage range of 15–25 °C documented as part of the product's stability dossier, ensuring that the analytical integrity confirmed at batch release is preserved through to the point of use.